{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:23:16Z","timestamp":1765610596191,"version":"3.40.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04766-9","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:39:52Z","timestamp":1742463592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alternative routes of drug administration: exposure of imatinib using different formulations"],"prefix":"10.1007","volume":"95","author":[{"given":"H. B.","family":"Fiebrich-Westra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Francken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-9758","authenticated-orcid":false,"given":"E. J.","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"4766_CR1","unstructured":"European Medicines Agency (2017) Summary of product characteristics: Imatinib teva 400\u00a0mg, filmomhulde tabletten. https:\/\/www.ema.europa.eu\/nl\/documents\/product-information\/imatinib-teva-epar-product-information_nl.pdf"},{"issue":"4","key":"4766_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00280-006-0409-0","volume":"60","author":"PH van Erp, Nielka","year":"2007","unstructured":"van Erp, Nielka PH, Oostendorp RL, Guchelaar H, Slens JHM, Gelderblom H (2007) Is rectal administration an alternative route for Imatinib?? Cancer Chemother Pharmacol 60(4):623\u2013624. https:\/\/doi.org\/10.1007\/s00280-006-0409-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4766_CR3","unstructured":"Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (2018) LNA mededeling: SyrSpend\u00ae SF. https:\/\/kennisbank.knmp.nl\/article\/LNA-mededelingen\/180901.html"},{"key":"4766_CR4","unstructured":"Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie LNA procedures bereiding: Suspensie, oraal. https:\/\/kennisbank.knmp.nl\/article\/LNA-procedures_bereiding\/Toedieningsvormen\/dranken\/B052.html. Updated 2015."},{"issue":"4","key":"4766_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","volume":"53","author":"H Yu","year":"2014","unstructured":"Yu H, Steeghs N, Nijenhuis CM, Schellens JHM, Beijnen JH, Huitema ADR (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the Pharmacokinetic targets. Clin Pharmacokinet 53(4):305\u2013325. https:\/\/doi.org\/10.1007\/s40262-014-0137-2","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"4766_CR6","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","volume":"18","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Fumagalli E, Rutkowski P et al (2012) Outcome of patients with platelet-derived growth factor receptor alpha-mutated Gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 18(16):4458\u20134464. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4766_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/0091270003262101","volume":"44","author":"B Peng","year":"2004","unstructured":"Peng B, Dutreix C, Mehring G et al (2004) Absolute bioavailability of Imatinib (glivec) orally versus intravenous infusion. J Clin Pharmacol 44(2):158\u2013162. https:\/\/doi.org\/10.1177\/0091270003262101","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4766_CR8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1592\/phco.26.7.903","volume":"26","author":"JH Beumer","year":"2006","unstructured":"Beumer JH, Natale JJ, Lagattuta TF, Raptis A, Egorin MJ (2006) Disposition of Imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy 26(7):903\u2013907. https:\/\/doi.org\/10.1592\/phco.26.7.903","journal-title":"Pharmacotherapy"},{"key":"4766_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-20298-8","author":"P Le Brun","year":"2023","unstructured":"Le Brun P, Crause-Manciet S, Kr\u00e4mer I, Smith J, Woerdenbag H (2023) Practical pharmaceutics: an internation guideline for the preparation, care and use of medical products. Springer. https:\/\/doi.org\/10.1007\/978-3-031-20298-8. Chap. 19: Rectal and Vaginal","journal-title":"Springer"},{"key":"4766_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3389\/fphar.2019.01196","volume":"10","author":"S Hua","year":"2019","unstructured":"Hua S (2019) Physiological and pharmaceutical considerations for rectal drug formulations. Front Pharmacol 10:1196. https:\/\/doi.org\/10.3389\/fphar.2019.01196","journal-title":"Front Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04766-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:39:55Z","timestamp":1742463595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04766-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4766"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04766-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}